Skip to content
Dr. Cannabis

Our sources

Every claim on this site traces to one of these 30 sources. If we could not source it, we did not publish it.

How we handle evidence

  • • Evidence tiers follow the categories used in the 2017 National Academies review. We do not upgrade a tier to make a page more persuasive.
  • • Where evidence exists that cannabis does not help — dementia, glaucoma, depression in chronic pain and MS — we publish that with the same prominence as a positive finding.
  • • Terpene effect claims are marked preclinical, because that is what they are. Several widely-repeated claims were searched for and not found in peer-reviewed human literature; those are not published here at all.
  • • AI writes explanatory prose around a recommendation that a deterministic rules engine has already produced from this sourced content. It never selects a cannabinoid, a dose, or a format, and its output is labelled where it appears.
  1. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.

    DOI 10.17226/24625Accessed 2026-08-15

  2. NASEM 2017, Committee Conclusions (summary PDF of all evidence-tier conclusions).

    Accessed 2026-08-15

  3. U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).

    Accessed 2026-08-15

  4. Epidiolex (cannabidiol) oral solution, prescribing information, revised 05/2026. NDA 210365.

    Accessed 2026-08-15

  5. U.S. Drug Enforcement Administration. Marijuana Rescheduling Regulatory Actions.

    Accessed 2026-08-15

  6. Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana. Published April 28, 2026.

    Accessed 2026-08-15

  7. Watts S, McElroy M, Migicovsky Z, Maassen H, van Velzen R, Myles S. Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants. 2021;7(10):1330-1334.

    DOI 10.1038/s41477-021-01003-yAccessed 2026-08-15

  8. Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.

    DOI 10.1371/journal.pone.0267498Accessed 2026-08-15

  9. Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. Frontiers in Plant Science. 2019;9:1969.

    DOI 10.3389/fpls.2018.01969Accessed 2026-08-15

  10. André R, Gomes AP, Pereira-Leite C, et al. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review. Pharmaceuticals. 2024;17(11):1543.

    DOI 10.3390/ph17111543Accessed 2026-08-15

  11. Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M. Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Frontiers in Pharmacology. 2020;11:359.

    DOI 10.3389/fphar.2020.00359Accessed 2026-08-15

  12. LaVigne JE, Hecksel R, Keresztes A, Streicher JM. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Scientific Reports. 2021;11:8232.

    DOI 10.1038/s41598-021-87740-8Accessed 2026-08-15

  13. Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105(26):9099-9104.

    DOI 10.1073/pnas.0803601105Accessed 2026-08-15

  14. Health Canada. Cannabis: Lower your risks. Modified 2019-06-14.

    Accessed 2026-08-15

  15. Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of Cannabis Research. 2021;3(1):22.

    DOI 10.1186/s42238-021-00073-1 / PMID 34215346Accessed 2026-08-15

  16. A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics. Journal of Cannabis Research. 2021.

    Accessed 2026-08-15

  17. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018;49:12-19.

    Accessed 2026-08-15

  18. Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic & Clinical Pharmacology & Toxicology. 2019;124(1):28-31.

    DOI 10.1111/bcpt.13152 / PMID 30326170Accessed 2026-08-15

  19. Monte AA, Shelton SK, Mills E, et al. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Annals of Internal Medicine. 2019;170(8):531-537.

    DOI 10.7326/M18-2809Accessed 2026-08-15

  20. Centers for Disease Control and Prevention. Cannabis Use During Pregnancy. Last reviewed 2025-01-31.

    Accessed 2026-08-15

  21. Centers for Disease Control and Prevention. Cannabis and Brain Health. Last reviewed 2024-02-15.

    Accessed 2026-08-15

  22. National Institute on Drug Abuse. Cannabis (Marijuana). Updated 2024-09-24.

    Accessed 2026-08-15

  23. American College of Obstetricians and Gynecologists. Cannabis Use During Pregnancy and Lactation (Clinical Consensus), October 2025.

    Accessed 2026-08-15

  24. Cannabinoid Hyperemesis Syndrome. StatPearls, NCBI Bookshelf. Last updated 2023-07-03.

    Accessed 2026-08-15

  25. National Conference of State Legislatures. State Medical Cannabis Laws. Page last updated 2026-06-01.

    Accessed 2026-08-15

  26. New York Office of Cannabis Management. Current OCM Licenses (open data).

    Accessed 2026-08-15

  27. Connecticut Department of Consumer Protection. Licensed Cannabis and Medical Marijuana Retail Locations (open data).

    Accessed 2026-08-15

  28. Pennsylvania Department of Health. Medical Marijuana Dispensaries (open data).

    Accessed 2026-08-15

  29. Oregon Liquor and Cannabis Commission. OLCC Cannabis Business Licenses & Endorsements (open data).

    Accessed 2026-08-15

  30. U.S. Census Bureau Geocoding Services API.

    Accessed 2026-08-15